ArticleFrontiers in neurology2022

Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk.

Robert K Lesniak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.